Don Tracy, Associate Editor

Results indicate that many people aged 50 to 80 years who take aspirin to prevent heart attacks and strokes don’t actually need to.

First of its kind study reported major improvements in skin clarity and itch relief in over two-thirds of participants.

In this Pharmaceutical Executive video interview, Chris Dowd, senior vice president of market development, ConnectiveRx, discusses the evolution of drug copay adjustment programs and the circumstances that fueled their controversy across industry, political, and healthcare community circles.

Relyvrio did not significantly alter amyotrophic lateral sclerosis disease progression as measured by the ALSFRS-R total score at Week 48 compared to placebo.

Starting June 1, Boehringer Ingelheim plans to cap inhaler products for respiratory diseases at $35 per month for eligible patients.

Eli Lilly continues to emphasize the potential harm that could come with using GLP-1 receptor agonists for off-label purposes.

Medication is the first tocilizumab biosimilar approved in the US for both IV and subcutaneous use for autoimmune diseases, such as rheumatoid arthritis and juvenile idiopathic arthritis.

Results from Phase IV RESPOND study indicate a significant reduction in plasma neurofilament light chain (NfL) levels.

Agreement to focus on research, option, and licensing for discovery of dual tumor-associated antigen-targeting antibodies.

Novel formulation of cabotegravir (CAB-ULA) allows for dosing intervals of at least four months.

This marks the first time that a hyaluronic acid dermal filler has received FDA approval for temple hollowing.

Letybo (letibotulinumtoxinA-wlbg) is expected to launch in in the United States toward the second half of the year for moderate-to-severe frown (glabellar) lines in adults.

Rebranding aims to align company with its parent company and other subsidiaries.

Teens to be included in both placebo and open label studies for QRX003, a potential treatment for Netherton syndrome.

JAMA commentary suggests that issues such as high costs, access, and equity will stop patients from obtaining GLP-1 agonists to treat obesity.

Phase III DAYBREAK study found consistent safety with Zeposia in patients with relapsing forms of multiple sclerosis.

Cardinal Health report highlights new biosimilar treatments, legislative developments, and multiple industry perspectives.

Commentary cites lower control over health plan costs and the potential bias for prescribing drugs through influence from drug manufacturers.

OSE-230 was developed to activate a unique mechanism for resolving chronic inflammation, focusing on modulation of macrophages and neutrophils.

The trial reportedly showcased significant weight reduction in those treated with VK2735, a dual GLP-1/GIP receptor agonist.

Agency identified several clinical deficiencies in the study, including insufficient evidence for roluperidone in the treatment of the negative symptoms associated with schizophrenia.

New label marks the first Bruton’s tyrosine kinase inhibitor to be approved with an oral suspension formulation.

Results of the study determined that adult flu vaccination rates among Medicaid populations were significantly low, highlighting other health inequities.

In an interview with Pharm Exec Associate Editor Don Tracy, Arun Krishna, VP, Head of US Lung Cancer Franchise, AstraZeneca, talks about the FDA's approval of TAGRISSO with the addition of chemotherapy in adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.

In the EAGLE-1 Phase III trial, gepotidacin met the primary efficacy endpoint of non-inferiorty to the current leading treatment for uncomplicated urogenital gonorrhea.

Collaboration aims to leverage Nhwa’s expertise in the country’s neuro-psychiatric health sector.

Results of a study conducted by the National Institutes of Health indicate that the Paxlovid prevented a substantial number of hospitalizations associated with COVID-19.

Funds expected to advance multiple programs into clinical studies, including FMC-376, which targets KRASG12C cancers.

Letter emphasizes the need to protect children from potentially harmful medical advice spread on social media.

Early-stage trial results indicate that NLRP3 inflammasome inhibitors were able to achieve nearly the same weight loss as Wegovy while also reducing inflammatory biomarkers linked to heart disease.